AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i), a catalyst for accelerating market access of breakthrough innovations to fight cancer. Under the terms of the agreement, C3i will deliver cell therapy products for Triumvira’s global Phase 1 and 2 clinical trials and has committed to underwrite an investment in the company.
“As part of the C3i mission, we not only build long-term partnerships but also ensure that the Canadians will have access to innovative technologies”
“We are very pleased to be working with C3i for the manufacturing at the Centre of Excellence in Cellular Therapy (CETC) GMP manufacturing facility. It is critical for us to have a supplier with specific expertise in cellular therapies, including cancer immunotherapies,” said Paul Lammers, MD, MSc, President & CEO, Triumvira. “As we work toward our goal of entering clinical development in 2019, we understand the importance of securing sufficient product from a state-of-the-art facility.”
Francois Bettez, President & CEO of C3i, commented, “We are honored to be supporting Triumvira Immunologics in their drug development program. Their selective and targeted approach to treat cancer aligns well with our manufacturing expertise as well as our commitment to bringing new treatment options to patients with cancer.”
As part of the deal, C3i also obtained a license to commercialize Triumvira’s lead product candidate, CD19 TAC, in Canada. “As part of the C3i mission, we not only build long-term partnerships but also ensure that the Canadians will have access to innovative technologies” commented Louisa Petropoulos, Director of Business Development at C3i.
The Centre of Excellence for Cellular Therapy (CETC), located at Hôpital Maisonneuve-Rosemont in Montreal, is a fully operational state-of-the art cGMP manufacturing facility for cellular therapies, including cancer immunotherapies and regenerative medicine. It is the only operational GMP validated center in Canada with commercial capacity, and is compliant with EMA, FDA and Health Canada regulatory requirements
About the Centre for Commercialisation of Cancer Immunotherapy
Established in 2016, the Centre for Commercialisation of Cancer Immunotherapy (C3i) is a Centre of Excellence for Commercialisation and Research from the Networks of Centres of Excellence. The mission is to accelerate access to innovative cancer immunotherapies for patients and offers an integrated structure for the development, translation and commercialization of groundbreaking therapies. C3i, which operates out of the Hôpital Maisonneuve- Rosemont in Montreal, Canada, combines four interacting units: GMP Manufacturing Unit for Regenerative Medicine and Cancer Immunotherapy; Biomarker-Diagnostic Unit; Clinical Research Unit; and Innovation and Commercialization Unit. For more information, visit: www.centrec3i.com
About Maisonneuve Rosemont Hospital (CIUSSS-EMTL)
Affiliated to the Université de Montréal, Hôpital Maisonneuve-Rosemont (HMR) is part of CIUSSS-EMTL. The HMR has a major research center of close to sixty researchers. There are four distinct sectors at the national and international levels: immuno-oncology, vision health, nephrology and cell therapy. Each year, the HMR receives more than 4,000 students, future physicians, nurses and health care professionals. HMR’s cancer program supports one of the largest bone marrow transplantation unit in Canada and is recognized a Canadian leader in cell therapy.
About Triumvira Immunologics
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to email@example.com
Beth Kurth, + 1 617-374-8800, Ext. 106
CIUSSS de l’Est-de-l’Île-de-Montréal
Centre of Commercialisation of Cancer Immunotherapy (C3i)
Francois Bettez, B. Sc. M.Sc., 514-755-2516
Chief Executive Officer